IMRN
Immuron Limited·Healthcare
0.79
0.875%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.6852W H: $2.39
IMRN NEWS
accessnewswire.com
Mar 5
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026 financial results and strategic update. The Flash Report notes that Immuron reported global product revenue of AUD $4.18 million for the six months ended December 31, 2025, representing approximately 5% growth compared to the prior-year period.
accessnewswire.com
Jan 22
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.50 following the Company's release of first-half fiscal year 2026 operating results. The Flash Report notes that Immuron reported global revenue of AUD$4.2 million for the six months ended December 31, 2025, representing a 5% increase compared to the prior-year period.
globenewswire.com
Jan 19
Immuron Reports Continued Sales Growth
Sales Highlights (unaudited): Global H1 sales AUD$4.2 million up 5% on prior comparative period (pcp) Q2 sales AUD$2.2 million up 11% on prior quarter Australia H1 sales AUD$3.3 million up 13% on prior comparative period (pcp) Q2 sales AUD$1.7 million up 11% on prior quarter Australian launch of ProIBS® Canada H1 sales AUD$56 thousand down 85% on prior comparative period (pcp) Q2 sales AUD$42 thousand up 191% on prior quarter USA H1 sales AUD$0.9 million up 17% on prior comparative period (pcp) Q2 sales AUD$0.4 million up 8% on prior quarter MELBOURNE, Australia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Continued Travelan® H1 sales growth ( +11% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing; (2) same store growth as a result of increased promotion and past promotions driving new customers and return customers respectively; (3) growth from new stores within banner groups in which we secured core ranging in FY25; (4) increased South East Asian travel.
